Literature DB >> 11281852

The immunomodulatory effects of anti-thyroid drugs are mediated via actions on thyroid cells, affecting thyrocyte-immunocyte signalling: a review.

R Volpé1.   

Abstract

The mechanism of action of the immunosuppressive effects of antithyroid drugs has remained a matter of controversy, despite our earlier contention that such effects in vivo were indirect; ie., it was our view that the drugs were acting on the thyroid cells, reducing their thyroid hormone production and other activities, with a consequent reduction in thyrocyte-immunocyte signalling. The reduction in the activation of CD4+ cells,the increased number and activation of CD8+ (and CD8+CDllb+) cells, and the reduction of soluble interleukin-2 receptors, thought once to be direct effects of the medication, are now shown to be due to amelioration of the hyperthyroidism. Thus the reduction in thyroid hormone production induced by the drugs is central to these actions. In addition, the iodination of thyroglobulin is inhibited by these agents, which may affect antigen presentation by the thyrocyte. Furthermore, there is now evidence that the thionamides interfere with thyrocyte expression of such molecules as Class I antigen, interleukin-1, interleukin-6, prostaglandin E2, and heat shock protein. The expression of thyrocyte Class II antigen is probably not inhibited by these drugs, although one group has shown that lectin-stimulated thyrocyte Class II expression is diminished by this treatment; this group postulated that this effect might be mediated by reduced interferon gamma production by T lymphocytes, but in vitro experiments do not corroborate this proposal. In any event, the actions as described of the effects of antithyroid drugs on the thyroid cells (particularly normalization of thyroid function) would certainly suffice to explain the diminution of thyroid antibodies (including thyroid stimulating antibody), the reduced immunological response, and the increased remission rate in Graves disease as a consequence of antithyroid drug therapy, without the need to invoke a direct immunosuppressive effect.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11281852     DOI: 10.2174/1381612013397898

Source DB:  PubMed          Journal:  Curr Pharm Des        ISSN: 1381-6128            Impact factor:   3.116


  9 in total

Review 1.  Relapse prediction in Graves´ disease: Towards mathematical modeling of clinical, immune and genetic markers.

Authors:  Christoph Langenstein; Diana Schork; Klaus Badenhoop; Eva Herrmann
Journal:  Rev Endocr Metab Disord       Date:  2016-12       Impact factor: 6.514

Review 2.  Graves' hyperthyroidism-related pancytopenia: a case report with literature review.

Authors:  Lorenzo Scappaticcio; Giuseppe Bellastella; Maria Ida Maiorino; Miriam Longo; Claudia Catalano; Katherine Esposito; Giuseppe Paolisso; Maria Rosaria Rizzo
Journal:  Hormones (Athens)       Date:  2020-07-08       Impact factor: 2.885

3.  The longer the antithyroid drug is used, the lower the relapse rate in Graves' disease: a retrospective multicenter cohort study in Korea.

Authors:  So Young Park; Bo Hyun Kim; Mijin Kim; A Ram Hong; Jun Park; Hyunju Park; Min Sun Choi; Tae Hyuk Kim; Sun Wook Kim; Ho-Cheol Kang; Jae Hoon Chung
Journal:  Endocrine       Date:  2021-04-15       Impact factor: 3.633

4.  Long-term outcome of Graves' disease patients treated in a region with iodine deficiency: relapse rate increases in years with thionamides.

Authors:  Neslihan Basçil Tütüncü; Tanju Tütüncü; Ali Ozgen; Tomris Erbas
Journal:  J Natl Med Assoc       Date:  2006-06       Impact factor: 1.798

5.  Altered balance between self-reactive T helper (Th)17 cells and Th10 cells and between full-length forkhead box protein 3 (FoxP3) and FoxP3 splice variants in Hashimoto's thyroiditis.

Authors:  B Kristensen; L Hegedüs; H O Madsen; T J Smith; C H Nielsen
Journal:  Clin Exp Immunol       Date:  2015-04       Impact factor: 4.330

6.  Impaired immune regulation after radioiodine therapy for Graves' disease and the protective effect of Methimazole.

Authors:  Sarah Côté-Bigras; Viet Tran; Sylvie Turcotte; Marek Rola-Pleszczynski; Jean Verreault; Diane Rottembourg
Journal:  Endocrine       Date:  2015-12-23       Impact factor: 3.633

Review 7.  Relation between therapy options for Graves' disease and the course of Graves' ophthalmopathy: a systematic review and meta-analysis.

Authors:  H X Li; N Xiang; W K Hu; X L Jiao
Journal:  J Endocrinol Invest       Date:  2016-05-24       Impact factor: 4.256

8.  A second course of antithyroid drug therapy for recurrent Graves' disease: an experience in endocrine practice.

Authors:  Xiaomei Liu; Wei Qiang; Xingjun Liu; Lianye Liu; Shu Liu; Aibo Gao; Shan Gao; Bingyin Shi
Journal:  Eur J Endocrinol       Date:  2014-12-02       Impact factor: 6.664

Review 9.  Graves' Disease: Can It Be Cured?

Authors:  Wilmar M Wiersinga
Journal:  Endocrinol Metab (Seoul)       Date:  2019-03
  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.